408 related articles for article (PubMed ID: 28623072)
21. Training Guidelines for Endovascular Ischemic Stroke Intervention: An International multi-society consensus document.
Interv Neuroradiol; 2016 Jun; 22(3):256-9. PubMed ID: 26957547
[TBL] [Abstract][Full Text] [Related]
22. Erratum for the Report "A precise measurement of the magnetic field in the corona of the black hole binary V404 Cygni" by Y. Dallilar, S. S. Eikenberry, A. Garner, R. D. Stelter, A. Gottlieb, P. Gandhi, P. Casella, V. S. Dhillon, T. R. Marsh, S. P. Littlefair, L. Hardy, R. Fender, K. Mooley, D. J. Walton, F. Fuerst, M. Bachetti, A. J. Castro-Tirado, M. Charcos, M. L. Edwards, N. M. Lasso-Cabrera, A. Marin-Franch, S. N. Raines, K. Ackley, J. G. Bennett, A. J. Cenarro, B. Chinn, H. V. Donoso, R. Frommeyer, K. Hanna, M. D. Herlevich, J. Julian, P. Miller, S. Mullin, C. H. Murphey, C. Packham, F. Varosi, C. Vega, C. Warner, A. N. Ramaprakash, M. Burse, S. Punnadi, P. Chordia, A. Gerarts, H. de Paz Martín, M. Martín Calero, R. Scarpa, S. Fernandez Acosta, W. M. Hernández Sánchez, B. Siegel, F. Francisco Pérez, H. D. Viera Martín, J. A. Rodríguez Losada, A. Nuñez, Á. Tejero, C. E. Martín González, C. Cabrera Rodríguez, J. Molgó, J. Esteban Rodriguez, J. I. Fernández Cáceres, L. A. Rodríguez García, M. Huertas Lopez, R. Dominguez, T. Gaggstatter, A. Cabrera Lavers, S. Geier, P. Pessev, A. Sarajedini.
Science; 2018 Apr; 360(6386):. PubMed ID: 29674566
[No Abstract] [Full Text] [Related]
23. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Department of Medicine; Department of Biostatistics and Computational Biology; Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston; Johns Hopkins University, Baltimore; University of Wisconsin Carbone Cancer Center; School of Medicine and Public Health; Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis; Mayo Clinic, Rochester, MN; University Hospitals Case Medical Center, Seidman Cancer Center; Cleveland Clinic Taussig Cancer Institute; Both in Cleveland; University of Virginia Cancer Center, Charlottesville; Comprehensive Cancer Centers of Nevada, Las Vegas; Siteman Cancer Center, Washington University School of Medicine, St. Louis; NorthShore University Health System, Evanston, IL; University of Michigan Comprehensive Cancer Center, Ann Arbor; Rutgers Cancer Institute of New Jersey, New Brunswick.N Engl J Med. 2015 Aug 20;373(8):737-46. [Epub 2015 Aug 5]. doi: 10.1056/NEJMoa1503747.
Scott E
Urol Oncol; 2017 Mar; 35(3):123. PubMed ID: 28159490
[TBL] [Abstract][Full Text] [Related]
24. Commentary on: "Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study." Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, Iversen P, Braeckman J, Heracek J, Baskin-Bey E, Ouatas T, Perabo F, Phung D, Hirmand M, Smith MR. Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address: bertrand.tombal@uclouvain.be. Aarhus University Hospital, Aarhus, Denmark. Herlev Hospital, Herlev, Denmark. AZ Groeninge Kortrijk, Kortrijk, Belgium. UZ Leuven, Leuven, Belgium. Klinik und Poliklinik für Urologie, RWTH University Aachen, Aachen, Germany. Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. UZ Brussel, Brussels, Belgium. Univerzita Karlova v Praze, Prague, Czech Republic. Astellas Pharma Global Development, Leiden, Netherlands. Astellas Pharma Global Development, Northbrook, IL, USA. Medivation Inc, San Francisco, CA, USA. Massachusetts General Hospital Cancer Center, Boston, MA, USA: Lancet Oncol. 2014 May;15(6):592-600; doi: 10.1016/S1470-2045(14)70129-9. [Epub 2014 Apr 14].
Trump D
Urol Oncol; 2016 May; 34(5):248-9. PubMed ID: 25937426
[TBL] [Abstract][Full Text] [Related]
25. Erratum for the Report "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma" by E. M. Van Allen, D. Miao, B. Schilling, S. A. Shukla, C. Blank, L. Zimmer, A. Sucker, U. Hillen, M. H. Geukes Foppen, S. M. Goldinger, J. Utikal, J. C. Hassel, B. Weide, K. C. Kaehler, C. Loquai, P. Mohr, R. Gutzmer, R. Dummer, S. Gabriel, C. J. Wu, D. Schadendorf, L. A. Garraway.
Science; 2016 Apr; 352(6283):. PubMed ID: 27081077
[No Abstract] [Full Text] [Related]
26. Erratum for the Report "Genomic correlates of response to CTLA-4 blockade in metastatic melanoma" by E. M. Van Allen, D. Miao, B. Schilling, S. A. Shukla, C. Blank, L. Zimmer, A. Sucker, U. Hillen, M. H. Geukes Foppen, S. M. Goldinger, J. Utikal, J. C. Hassel, B. Weide, K. C. Kaehler, C. Loquai, P. Mohr, R. Gutzmer, R. Dummer, S. Gabriel, C. J. Wu, D. Schadendorf, L. A. Garraway.
Science; 2015 Nov; 350(6262):aad8366. PubMed ID: 26564858
[No Abstract] [Full Text] [Related]
27. Re: Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival: A. Abugharib, W. C. Jackson, V. Tumati, R. T. Dess, J. Y. Lee, S. G. Zhao, M. Soliman, Z. S. Zumsteg, R. Mehra, F. Y. Feng, T. M. Morgan, N. Desai and D. E. Spratt J Urol 2017;197:662-668.
Taguchi S; Fukuhara H; Homma Y
J Urol; 2017 Jul; 198(1):212-214. PubMed ID: 28384440
[No Abstract] [Full Text] [Related]
28. Words of wisdom. Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reide AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper C, Kaye S, Dearnaley D, Lee G, de Bono JS. J Clin Oncol 2008;26:4563-71.
Eisenberger MA
Eur Urol; 2009 Jan; 55(1):248. PubMed ID: 20050017
[No Abstract] [Full Text] [Related]
29. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
Trump DL
Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
[TBL] [Abstract][Full Text] [Related]
30. Commentary on: "Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy." Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N. Nature. 2016 May 25;533(7604):547-51.
Lee BH
Urol Oncol; 2017 Sep; 35(9):576. PubMed ID: 28789926
[TBL] [Abstract][Full Text] [Related]
31. LITERATURE ABSTRACTS.
J Texture Stud; 1971 Dec; 2(4):502-509. PubMed ID: 28370130
[TBL] [Abstract][Full Text] [Related]
32. Determining the frequency of pathogenic germline variants from exome sequencing in patients with castrate-resistant prostate cancer.
Hart SN; Ellingson MS; Schahl K; Vedell PT; Carlson RE; Sinnwell JP; Barman P; Sicotte H; Eckel-Passow JE; Wang L; Kalari KR; Qin R; Kruisselbrink TM; Jimenez RE; Bryce AH; Tan W; Weinshilboum R; Wang L; Kohli M
BMJ Open; 2016 Apr; 6(4):e010332. PubMed ID: 27084275
[TBL] [Abstract][Full Text] [Related]
33. Allele frequencies and haplotypes of eight Y-short tandem repeats in Bantu population living in Central Africa.
Lecerf M; Filali M; Grésenguet G; Ndjoyi-Mbiguino A; Le Goff J; de Mazancourt P; Bélec L
Forensic Sci Int; 2007 Sep; 171(2-3):212-5. PubMed ID: 16769189
[TBL] [Abstract][Full Text] [Related]
34. Erratum for the Research Article: "Genomic profiling of ER
Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760583
[No Abstract] [Full Text] [Related]
35. Re: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer: S. Loeb, M. G. Sanda, D. L. Broyles, S. S. Shin, C. H. Bangma, J. T. Wei, A. W. Partin, G. G. Klee, K. M. Slawin, L. S. Marks, R. H. N. van Schaik, D. W. Chan, L. J. Sokoll, A. B. Cruz, I. A. Mizrahi and W. J. Catalona J Urol 2015;193:1163-1169.
Shah N; Ioffe V
J Urol; 2015 Dec; 194(6):1825-6. PubMed ID: 26354886
[No Abstract] [Full Text] [Related]
36. Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in
Watson AP; Shabaneh A; Wang J; Dehm SM; Rao A; Ryan CJ
Am J Clin Exp Urol; 2020; 8(4):106-115. PubMed ID: 32929406
[TBL] [Abstract][Full Text] [Related]
37. Genomic Profiling of Prostate Cancer: An Updated Review.
Hatano K; Nonomura N
World J Mens Health; 2022 Jul; 40(3):368-379. PubMed ID: 34448375
[TBL] [Abstract][Full Text] [Related]
38. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
39. Matrix Solid-Phase Dispersion Combined with HPLC-DAD for Simultaneous Determination of Nine Lignans in Saururus chinensis.
Chen H; Ji T; Chen J; Li X
J Chromatogr Sci; 2019 Feb; 57(2):186-193. PubMed ID: 30272133
[TBL] [Abstract][Full Text] [Related]
40. Commentary on "denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial." M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damião, T.L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gómez-Veiga, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, C. Goessl, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.: Lancet 2012;379:39-46 [Epub;2011, November 15].
Trump DL
Urol Oncol; 2012 Sep; 30(5):747. PubMed ID: 23021561
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
